PriceTargets.com logo

Zynerba Pharmaceuticals - ZYNE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.11
  • Forecasted Upside: -14.62%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.30 As of 10/11/2023 09:00 PM ET
▲ +0.03 (2.36%)
Get New Zynerba Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYNE

Analyst Price Target is $1.11
▼ -14.62% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Zynerba Pharmaceuticals in the last 3 months. The average price target is $1.11, with a high forecast of $1.11 and a low forecast of $1.11. The average price target represents a -14.62% upside from the last price of $1.30.

This chart shows the closing price for ZYNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Zynerba Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$10.00 ➝ $1.11Low
8/15/2023HC WainwrightDowngradeBuy ➝ NeutralLow
8/14/2023LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
3/31/2023Cantor FitzgeraldReiterated RatingOverweightLow
11/1/2022HC WainwrightDowngradeBuy ➝ NeutralLow
6/23/2022Canaccord Genuity GroupReiterated RatingBuy$9.00 ➝ $11.00Low
6/23/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$9.00 ➝ $11.00Low
11/18/2021HC WainwrightReiterated RatingBuy$9.00High
9/21/2021HC WainwrightReiterated RatingBuy$9.00Medium
9/13/2021UBS GroupReiterated RatingPositiveLow
5/6/2021Cantor FitzgeraldBoost TargetOverweight$6.00 ➝ $8.00High
3/10/2021Roth CapitalLower TargetBuy$8.00 ➝ $7.25High
12/21/2020HC WainwrightLower TargetBuy$12.00 ➝ $9.00Low
9/14/2020Needham & Company LLCReiterated RatingHoldMedium
8/10/2020Needham & Company LLCReiterated RatingHoldMedium
7/1/2020HC WainwrightReiterated RatingBuy$12.00Medium
7/1/2020Needham & Company LLCDowngradeBuy ➝ HoldMedium
7/1/2020Cantor FitzgeraldLower TargetOverweight$24.00 ➝ $8.00Medium
6/29/2020LADENBURG THALM/SH SHReiterated RatingBuy$26.00Medium
5/28/2020Cantor FitzgeraldBoost TargetOverweight$21.00 ➝ $24.00High
5/22/2020Cantor FitzgeraldBoost TargetOverweight$12.00 ➝ $21.00High
4/16/2020Needham & Company LLCReiterated RatingBuy$16.00High
2/20/2020HC WainwrightReiterated RatingBuyLow
12/31/2019Roth CapitalInitiated CoverageBuy$12.00High
10/21/2019Needham & Company LLCInitiated CoverageBuy$18.00High
9/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00High
9/16/2019Jefferies Financial GroupReiterated RatingHold$11.00Low
5/31/2019Cantor FitzgeraldBoost TargetOverweight$12.00 ➝ $22.00Medium
5/30/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00Medium
5/6/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00Low
4/30/2019Roth CapitalInitiated CoverageBuy$36.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Zynerba Pharmaceuticals logo
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Read More

Today's Range

Now: $1.30
Low: $1.26
High: $1.34

50 Day Range

MA: $1.30
Low: $1.21
High: $1.39

52 Week Range

Now: $1.30
Low: $0.25
High: $1.40

Volume

862,700 shs

Average Volume

515,333 shs

Market Capitalization

$70.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Zynerba Pharmaceuticals?

The following sell-side analysts have issued reports on Zynerba Pharmaceuticals in the last year: Canaccord Genuity Group Inc., HC Wainwright, LADENBURG THALM/SH SH, and StockNews.com.
View the latest analyst ratings for ZYNE.

What is the current price target for Zynerba Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Zynerba Pharmaceuticals in the last year. Their average twelve-month price target is $1.11, suggesting a possible downside of 14.6%. Canaccord Genuity Group Inc. has the highest price target set, predicting ZYNE will reach $1.11 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $1.11 for Zynerba Pharmaceuticals in the next year.
View the latest price targets for ZYNE.

What is the current consensus analyst rating for Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ZYNE, but not buy more shares or sell existing shares.
View the latest ratings for ZYNE.

What other companies compete with Zynerba Pharmaceuticals?

Other companies that are similar to Zynerba Pharmaceuticals include Carisma Therapeutics, Corvus Pharmaceuticals, Rallybio, Immix Biopharma and Celularity. Learn More about companies similar to Zynerba Pharmaceuticals.

How do I contact Zynerba Pharmaceuticals' investor relations team?

Zynerba Pharmaceuticals' physical mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company's listed phone number is (484) 581-7505 and its investor relations email address is [email protected]. The official website for Zynerba Pharmaceuticals is www.zynerba.com. Learn More about contacing Zynerba Pharmaceuticals investor relations.